These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 27734263)
1. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma. Higashi T; Hayashi H; Kitano Y; Yamamura K; Kaida T; Arima K; Taki K; Nakagawa S; Okabe H; Nitta H; Imai K; Hashimoto D; Chikamoto A; Beppu T; Baba H Med Oncol; 2016 Nov; 33(11):123. PubMed ID: 27734263 [TBL] [Abstract][Full Text] [Related]
2. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487 [TBL] [Abstract][Full Text] [Related]
3. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258 [TBL] [Abstract][Full Text] [Related]
4. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression. Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216 [TBL] [Abstract][Full Text] [Related]
5. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. Yang SY; Wang CC; Chen KD; Liu YW; Lin CC; Chuang CH; Tsai YC; Yao CC; Yen YH; Hsiao CC; Hu TH; Tsai MC BMC Cancer; 2021 Jan; 21(1):70. PubMed ID: 33446127 [TBL] [Abstract][Full Text] [Related]
6. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750 [TBL] [Abstract][Full Text] [Related]
7. Metabolic control of YAP and TAZ by the mevalonate pathway. Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687 [TBL] [Abstract][Full Text] [Related]
8. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway. Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777 [TBL] [Abstract][Full Text] [Related]
9. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430 [TBL] [Abstract][Full Text] [Related]
10. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Kawaguchi Y; Sakamoto Y; Ito D; Ito K; Arita J; Akamatsu N; Kaneko J; Hasegawa K; Moriya K; Kokudo N Biosci Trends; 2017 Nov; 11(5):574-580. PubMed ID: 29081488 [TBL] [Abstract][Full Text] [Related]
11. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization. Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992 [TBL] [Abstract][Full Text] [Related]
12. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells. Higashi T; Hayashi H; Ishimoto T; Takeyama H; Kaida T; Arima K; Taki K; Sakamoto K; Kuroki H; Okabe H; Nitta H; Hashimoto D; Chikamoto A; Beppu T; Baba H Br J Cancer; 2015 Jul; 113(2):252-8. PubMed ID: 26125451 [TBL] [Abstract][Full Text] [Related]
13. TAZ and YAP are frequently activated oncoproteins in sarcomas. Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148 [TBL] [Abstract][Full Text] [Related]
14. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway. Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis. Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820 [TBL] [Abstract][Full Text] [Related]
17. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Ahn EY; Kim JS; Kim GJ; Park YN Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797 [TBL] [Abstract][Full Text] [Related]
18. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation. Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699 [TBL] [Abstract][Full Text] [Related]
19. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner. Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386 [TBL] [Abstract][Full Text] [Related]
20. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]